Carolyn Bertozzi, PhD, Ann T. and Robert M. Bass Professor of Chemistry and, by courtesy, of Chemical and Systems Biology and Radiology, Stanford University Schools of Humanities & Sciences and Medicine, Investigator, Howard Hughes Medical Institute.
Research Description: For 20 years, Dr. Bertozzi’s lab has worked at the intersection of chemistry and glycobiology. Her research includes development of chemical transformations tailored for living systems, a field termed bioorthogonal chemistry, as well as technologies for imaging biomolecules in animal disease models. Her lab also develops mass spectrometry-based methods for glycoproteomics and next-generation biotherapeutics targeting altered glycosylation in cancer. Her lab is fully equipped for chemical synthesis, molecular and cell biology, fluorescence imaging, zebrafish manipulations, and work with BSL3 organisms. Dr. Bertozzi recently published a study describing ultrasensitive methods for detecting antibodies in serum using a method we developed called ‘agglutination-PCR’ (Tsai et al 2016 cited below). This includes detection of T1D autoantibodies at concentrations 3 orders of magnitude than standard assays like ELISAs. She and her colleagues formed a company, Enable Biosciences, that is developing this test for early detection of T1D, which was funded by an NIH SIBR award. Though new to diabetes research, membership of Dr. Bertozzi in the Stanford DRC is aligned with its mission to attract, support and enable established distinguished investigators to diabetes research.
Selected relevant publications (Stanford DRC Members in BOLD):
1. Tsai, C., Robinson, P. V., Spencer, C. A., Bertozzi, C. R. Ultrasensitive antibody detection by agglutination-PCR (ADAP). ACS Cent. Sci. 2016, 2, 139-147.